Corvus Pharma Director Boosts Stake; 1.4M Warrants Exercised
Rhea-AI Filing Summary
Corvus Pharmaceuticals, Inc. (CRVS) – Form 4 insider activity dated 06/27/2025
Director and 10% owner Peter A. Thompson, acting through OrbiMed Private Investments V, LP (OPI V), exercised 1,397,684 common stock warrants at $3.50 just before their 06/30/2025 expiry. The warrants were settled on a cashless basis: the issuer withheld 1,176,332 shares (coded “S”) to fund the exercise, and issued 221,352 new shares to OPI V (coded “X”). Following the transactions, Thompson/OPI V’s indirect beneficial ownership stands at 7,165,006 shares.
The filing shows a small net increase in insider ownership and a modest share-count expansion for the company. No open-market sales were reported; the disposition reflects internal share withholding rather than a public sale.
Positive
- Insider confidence: Director/10% owner increased net holdings by 221,352 shares through warrant exercise.
- No open-market selling: Shares withheld to cover exercise price, avoiding additional market supply.
Negative
- Minor dilution: Issuance of 221,352 new shares slightly increases outstanding share count.
Insights
TL;DR — Insider exercises expiring warrants, nets 221k new shares; marginal dilution, signals continued commitment.
The cashless exercise converts near-term expiring warrants without cash outlay, avoiding market overhang. While 1.18 million shares were technically “sold,” they were withheld by the issuer, so no fresh supply hit the market. The net issuance of 221,352 shares (≈0.3% of a 70 m share base if similar-sized peers are used) is immaterial dilution. Insider now holds 7.17 m shares, reinforcing strategic alignment. Overall impact is neutral-to-slightly positive, indicating confidence but lacking broader financial implications.
TL;DR — Routine Section 16 filing; ownership clarity maintained, no governance red flags detected.
The disclosure satisfies Section 16 requirements and clarifies indirect ownership through OrbiMed entities. All disclaimers regarding beneficial ownership are standard. The conversion ahead of warrant expiry demonstrates orderly insider behavior, limiting potential conflicts. No evidence of aggressive selling or rule-10b5-1 usage is noted. Consequently, governance risk remains unchanged.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| X | Common Warrants (right to buy) | 1,397,684 | $0.00 | -- |
| X | Common Stock | 1,397,684 | $3.50 | $4.89M |
| Sale | Common Stock | 1,176,332 | $4.1586 | $4.89M |
Footnotes (1)
- On June 27, 2025, OrbiMed Private Investments V, LP ("OPI V") exercised common warrants ("Warrants") to purchase 1,397,684 shares of the Issuer's Common Stock for $3.50 per share. OPI V paid the exercise price on a cashless basis, resulting in the Issuer withholding 1,176,332 of the Warrant shares to pay the exercise price and issuing to OPI V the remaining 221,352 shares. These securities are held of record by OPI V. OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V. The Reporting Person is a member of Advisors. Each of the Reporting Person, OrbiMed Advisors, and GP V disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
